Clinical trial
Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer
NCT00158886 · GlaxoSmithKline, Industry · Terminated
Key facts
| NCT number | NCT00158886 |
|---|---|
| Title | Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer |
| Official title | A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Cancer |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug, Radiation |
| Interventions | Topotecan, Radiation therapy |
| Enrollment | 26 |
| Start date | Nov 8, 2001 |
| Primary completion | Aug 11, 2006 |
| Completion | Aug 11, 2006 |
| First posted | Sep 12, 2005 |
| Last update posted | Nov 14, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: